… of complement … complement inhibitors targeting various complement pathways are in
clinical trials for the treatment of HSCT-TMA. In this article, we review the role of the complement …

… the use of anti-inflammatory therapies and heparin, respectively. We suggest that
complement-blocking … have commonalities with thrombotic microangiopathies that respond to the …

… history of macular degeneration (a proxy for complement activation disorders) and history
of coagulation disorders (thrombocytopenia, thrombosis and hemorrhage) are risk factors for …

… of microvascular thrombosis frequently observed in patients … thrombosis, Magro et al.
identified terminal complement (C5d-… of the complement pathway to the process of thrombotic …

… Complement activation, in conjunction with neutrophilia … inflammation, and thrombotic
events, resulting in permanent multiorgan damage. NETs initiate arterial and venous thrombosis …

… complement-mediated thrombotic microangiopathies with renal manifestations such as
atypical haemolytic uraemic syndrome (aHUS) 69,70 . Both C3 glomerulopathy and aHUS share …

… (aHUS) (13, 14), two devastating complement-mediated thrombotic disorders, underlines
the value of bringing these two biochemical proteolytic pathways together in the clinic. …

… that complement and neutrophils contribute to the maladaptive immune response that fuels
hyperinflammation and thrombotic … Here, we investigated how complement interacts with the …

… has further increased interest in complement as a target for … complement activation is
associated with thrombotic events in APS, and that patient derived aPL directly activate complement…

… It is clear that complement … of complement regulatory proteins (ie PNH) or due to viral
infection (ie SARS‐CoV‐2), and can lead to significant tissue damage and importantly thrombosis …